The first issue is whether there is a dose-effect relationship between Ang-(1–7) and DCM, whether Ang-(1–7) is superior to ACE inhibition in the treatment of DCM and whether the combination of Ang-(1–7) and ACE inhibition is better than Ang-(1–7) alone in alleviating DCM. The gene discussed is ACE; the disease is familial dilated cardiomyopathy.